Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(R)-Lansoprazole (T 168390) 是Lansoprazole 的R 型异构体。Lansoprazole 是口服有效的质子泵抑制剂,能抑制胃酸生成。Lansoprazole 是中性鞘磷脂酶(N-SMase)的抑制剂(外泌体抑制剂),能透过血脑屏障。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
50 mg | ¥ 269 | 现货 | ||
100 mg | ¥ 383 | 现货 | ||
200 mg | ¥ 540 | 现货 | ||
500 mg | ¥ 887 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 423 | 现货 |
产品描述 | (R)-Lansoprazole (T 168390) is the R-isomer of lansoprazole and a substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity.Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) |
体外活性 | Dexlansoprazole, constitutes >80% of circulating drug after oral administration of lansoprazole, provides lower clearance and 5-fold greater systemic exposure than the S-enantiomer following oral administration of lansoprazole. Dexlansoprazole MR is a modified release formulation of dexlansoprazole, which employs a novel Dual Delayed Release (DDR) technology that delivers the drug in two discrete phases of release, thereby inhibiting newly activated proton pumps that turn over following initial PPI inactivation of H+,K+-ATPase. Dexlansoprazole MR maintains plasma drug concentrations above the threshold level longer than lansoprazole at all doses, resulting in an optimized drug exposure-intragastric pH relationship. [1] Dexlansoprazole selectively suppresses gastric acid secretion by direct inhibition of the H+K+-ATPase proton pump in the gastric parietal cell, inhibition of this cell membrane enzyme ultimately blocks the final step in acid production. [2] |
别名 | Dexlansoprazole, 右旋兰索拉唑, T 168390, TAK 390, R-(+)-Lansoprazole |
分子量 | 369.36 |
分子式 | C16H14F3N3O2S |
CAS No. | 138530-94-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 74 mg/mL (200.34 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.7074 mL | 13.5369 mL | 27.0739 mL | 67.6846 mL |
5 mM | 0.5415 mL | 2.7074 mL | 5.4148 mL | 13.5369 mL | |
10 mM | 0.2707 mL | 1.3537 mL | 2.7074 mL | 6.7685 mL | |
20 mM | 0.1354 mL | 0.6768 mL | 1.3537 mL | 3.3842 mL | |
50 mM | 0.0541 mL | 0.2707 mL | 0.5415 mL | 1.3537 mL | |
100 mM | 0.0271 mL | 0.1354 mL | 0.2707 mL | 0.6768 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
(R)-Lansoprazole 138530-94-6 Membrane transporter/Ion channel Proton pump Inhibitor Lansoprazole Dexlansoprazole Proton Pump T-168390 inhibit T168390 右旋兰索拉唑 R-Lansoprazole TAK-390 TAK390 (R) Lansoprazole T 168390 TAK 390 R-(+)-Lansoprazole (R)Lansoprazole inhibitor